hotspot -WSS

hotspot

author：fashion 2025-09-27 09:38:13 - browse：8791

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： High breast density mammograms need follow

WSS

Mass General, Mayo Clinic look to monetize custom

Readout Newsletter: BridgeBio, Akero, and human embryo models

Head of FDA's diagnostics center, who led through Covid, retires

Head of FDA's diagnostics center, who led through Covid, retires

Streamlined flu vaccines recommended by FDA advisory panel

FDA endorses new sterilization method for medical devices

leisure time

hotspot

leisure time

Heart attack and stroke risk calculators need revising

Pumping milk in bathrooms at health conferences is common

Trump demands the U.S. pay no more for drugs than other countries … again

Medicare drug price lawsuits could be good politics for Biden

The high cost of giving birth even with insurance

Ozempic has benefits for kidney disease as well as diabetes

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Medicare proposal to cover medical devices draws a mixed reaction

TikTok, Instagram influencers need more rules for drug ads

knowledge

To bolster infectious disease surveillance, genomics powerhouses team up

Maisha Meds is a PBM, but don't call it that

There's an unseen cost to disruptive road

Pregnant women don't need prenatal multivitamins, study concludes

TikTok, Instagram influencers need more rules for drug ads

There's an unseen cost to disruptive road

focus

leisure time

leisure time

leisure time